Emtricitabine (BioDeep_00000002948)

 

Secondary id: BioDeep_00000858435

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one

化学式: C8H10FN3O3S (247.0427)
中文名称: 恩曲他滨
谱图信息: 最多检出来源 Homo sapiens(blood) 49.83%

分子结构信息

SMILES: c1c(c(N)nc(=O)n1[C@@H]1CS[C@H](CO)O1)F
InChI: InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)

描述信息

Emtricitabine is only found in individuals that have used or taken this drug. It is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. Emtricitabine works by inhibiting reverse transcriptase (RT), an enzyme that allows the virus to multiply by copying HIV RNA into new viral DNA. The drug competes with the reverse transcriptases natural substrate deoxycytidine 5-triphosphate and also becomes incorporated into viral DNA. This is a result of emtricitabine being a synthetic nucleoside analogue of cytidine. It is phosphorylated by cellular enzymes to form emtricitabine 5-triphosphate which competes with the natural substrate deoxycytidine 5-triphosphate and becomes incorporated into nascent viral DNA, resulting in early chain termination. By inhibiting HIV-1 reverse transcriptase, emtricitabine can help to lower the amount of HIV (viral load) in a patients body and can indirectly increase the number of immune system cells (T cells or CD4+ T-cells). Both of these changes are associated with healthier immune systems and a decreased likelihood of serious illness. Emtricitabine is always used in conjunction with other HIV medicine to treat people with HIV infection.
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors
C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97452 - Nucleoside Reverse Transcriptase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent
CONFIDENCE standard compound; EAWAG_UCHEM_ID 3106
Same as: D01199

同义名列表

22 个代谢物同义名

4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; (-)-cis-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 4-Amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; 4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one; (-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-beta-2,3-Dideoxy-5-fluoro-3-thiacytidine; Beta L 2,3 Dideoxy 5 fluoro 3 thiacytidine; beta-L-2,3-Dideoxy-5-fluoro-3-thiacytidine; (-)-b-2,3-Dideoxy-5-fluoro-3-thiacytidine; (-)-Β-2,3-dideoxy-5-fluoro-3-thiacytidine; (-)-2,3-Dideoxy-5-fluoro-3-thiacytidine; (-)-2-Deoxy-5-fluoro-3-thiacytidine; (-)-Emtricitabine; ABBR FTC; Emtricitabine; Coviracil; Emtriva; Racivir; (-)-FTC; Emtricitabine



数据库引用编号

34 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 6 ABCB1, ALB, CCR5, CYP3A4, EGFR, SRY
Endosome membrane 2 EGFR, HLA-B
Endoplasmic reticulum membrane 4 CD4, CYP3A4, EGFR, HLA-B
Mitochondrion membrane 1 ABCG2
Nucleus 3 ALB, EGFR, SRY
cytosol 2 ALB, GPT
mitochondrial membrane 1 ABCG2
centrosome 1 ALB
nucleoplasm 2 ABCG2, SRY
Cell membrane 8 ABCB1, ABCC1, ABCG2, CCR5, CD4, CD8A, EGFR, HLA-B
ruffle membrane 1 EGFR
Early endosome membrane 2 EGFR, HLA-B
Multi-pass membrane protein 6 ABCB1, ABCC1, ABCC2, ABCC4, ABCG2, CCR5
cell junction 1 EGFR
cell surface 5 ABCB1, ABCC2, CCR5, EGFR, HLA-B
glutamatergic synapse 1 EGFR
Golgi apparatus 3 ABCC4, ALB, HLA-B
Golgi membrane 3 EGFR, HLA-B, INS
lysosomal membrane 1 HLA-B
endosome 2 CCR5, EGFR
plasma membrane 12 ABCB1, ABCC1, ABCC2, ABCC4, ABCG2, CCR5, CD4, CD8A, EGFR, HLA-B, IFNLR1, RASL12
Membrane 10 ABCB1, ABCC1, ABCC2, ABCC4, ABCG2, CCR5, CYP3A4, EGFR, HLA-B, IFNLR1
apical plasma membrane 6 ABCB1, ABCC1, ABCC2, ABCC4, ABCG2, EGFR
basolateral plasma membrane 3 ABCC1, ABCC4, EGFR
extracellular exosome 5 ABCB1, ABCC1, ALB, GPT, HLA-B
Lysosome membrane 1 HLA-B
endoplasmic reticulum 2 ALB, HLA-B
extracellular space 6 ALB, CRP, EGFR, HLA-B, IL6, INS
perinuclear region of cytoplasm 1 EGFR
intercellular canaliculus 1 ABCC2
protein-containing complex 2 ALB, EGFR
intracellular membrane-bounded organelle 1 CYP3A4
Microsome membrane 1 CYP3A4
Single-pass type I membrane protein 5 CD4, CD8A, EGFR, HLA-B, IFNLR1
Secreted 4 ALB, CRP, IL6, INS
extracellular region 5 ALB, CD8A, CRP, IL6, INS
Single-pass membrane protein 1 HLA-B
[Isoform 2]: Secreted 1 CD8A
anchoring junction 1 ALB
nuclear membrane 1 EGFR
external side of plasma membrane 4 CCR5, CD4, CD8A, HLA-B
nucleolus 1 ABCC4
Early endosome 1 CD4
Apical cell membrane 4 ABCB1, ABCC2, ABCC4, ABCG2
Membrane raft 3 ABCG2, CD4, EGFR
focal adhesion 1 EGFR
intracellular vesicle 1 EGFR
lateral plasma membrane 1 ABCC1
nuclear speck 1 SRY
receptor complex 2 CD8A, EGFR
ciliary basal body 1 ALB
chromatin 1 SRY
phagocytic vesicle membrane 1 HLA-B
centriole 1 ALB
brush border membrane 1 ABCG2
spindle pole 1 ALB
blood microparticle 1 ALB
Basolateral cell membrane 1 ABCC4
Recycling endosome membrane 1 HLA-B
endosome lumen 1 INS
Nucleus speckle 1 SRY
basal plasma membrane 2 ABCC1, EGFR
synaptic membrane 1 EGFR
platelet dense granule membrane 1 ABCC4
plasma membrane raft 1 CD8A
secretory granule lumen 1 INS
secretory granule membrane 1 HLA-B
Golgi lumen 1 INS
endoplasmic reticulum lumen 4 ALB, CD4, IL6, INS
platelet alpha granule lumen 1 ALB
transport vesicle 1 INS
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
ER to Golgi transport vesicle membrane 1 HLA-B
clathrin-coated endocytic vesicle membrane 2 CD4, EGFR
external side of apical plasma membrane 3 ABCB1, ABCC4, ABCG2
lumenal side of endoplasmic reticulum membrane 1 HLA-B
[Isoform 1]: Cell membrane 1 CD8A
multivesicular body, internal vesicle lumen 1 EGFR
Shc-EGFR complex 1 EGFR
T cell receptor complex 2 CD4, CD8A
MHC class I protein complex 1 HLA-B
MHC class II protein complex 1 HLA-B
interleukin-6 receptor complex 1 IL6
ciliary transition fiber 1 ALB
interleukin-28 receptor complex 1 IFNLR1


文献列表

  • Jen-Yu Hsu, Hsin-Yun Sun, Ling-Ya Chen, Sui-Yuan Chang, Yu-Chung Chuang, Yu-Shan Huang, Yi-Ching Su, Wen-Chun Liu, Chien-Ching Hung. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide. Journal of global antimicrobial resistance. 2024 Mar; 36(?):426-435. doi: 10.1016/j.jgar.2023.10.012. [PMID: 37923129]
  • Chloe Orkin, Jean-Michel Molina, Pedro Cahn, Johannes Lombaard, Khuanchai Supparatpinyo, Sushma Kumar, Havilland Campbell, Hong Wan, Valerie Teal, Zhi Jin Xu, Ernest Asante-Appiah, Peter Sklar, Hedy Teppler, Rima Lahoulou. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. The lancet. HIV. 2024 Feb; 11(2):e75-e85. doi: 10.1016/s2352-3018(23)00258-8. [PMID: 38141637]
  • Jiang Xiao, Guiju Gao, Yi Ding, Jialu Li, Chengyu Gao, Qiuhua Xu, Liang Wu, Hongyuan Liang, Liang Ni, Fang Wang, Yujiao Duan, Di Yang, Hongxin Zhao. Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients. Chinese medical journal. 2023 Dec; 136(24):2931-2937. doi: 10.1097/cm9.0000000000002939. [PMID: 38032036]
  • Lin Gan, Xiaoxin Xie, Yanhua Fu, Yebing Song, Chunli Song, Tingting Ren, Hai Long. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study. Expert review of anti-infective therapy. 2023 Dec; ?(?):1-7. doi: 10.1080/14787210.2023.2292544. [PMID: 38058002]
  • Yinghua Wei, Jin Li, Ruhong Xu, Li Wen, Yiming Deng, Lixia He, Huijun Zhong, Yanhao Wang. Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1. Chinese medical journal. 2023 Nov; ?(?):. doi: 10.1097/cm9.0000000000002907. [PMID: 37914678]
  • Sandra Rotea-Salvo, Víctor Giménez-Arufe, Alejandro Martínez-Pradeda, Carla Fernández-Oliveira, Álvaro Mena-de-Cea, Luis Margusino-Framiñán, Isabel Martín-Herranz, Purificación Cid-Silva. Lipid profile changes associated with antiretroviral therapies in a real-world cohort. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2023 Sep; 47(5):T210-T217. doi: 10.1016/j.farma.2023.07.005. [PMID: 37673703]
  • Leonardo Calza, Vincenzo Colangeli, Giulia Pensalfine, Lucia Appolloni, Salvatore Vitale, Isabella Bon, Pierluigi Viale. Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. International journal of STD & AIDS. 2023 Aug; ?(?):9564624231195084. doi: 10.1177/09564624231195084. [PMID: 37565832]
  • Sandra Rotea-Salvo, Víctor Giménez-Arufe, Alejandro Martínez-Pradeda, Carla Fernández-Oliveira, Álvaro Mena-de-Cea, Luis Margusino-Framiñán, Isabel Martín-Herranz, Purificación Cid-Silva. Lipid profile changes associated with antiretroviral therapies in a real-world cohort. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2023 Jun; ?(?):. doi: 10.1016/j.farma.2023.04.007. [PMID: 37349200]
  • Alessandro Lazzaro, Diana Bianchini, Elio Gentilini Cacciola, Ivano Mezzaroma, Mario Falciano, Carolina Andreoni, Caterina Fimiani, Letizia Santinelli, Luca Maddaloni, Ginevra Bugani, Giancarlo Ceccarelli, Claudio Maria Mastroianni, Gabriella d'Ettorre. Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort. Viruses. 2023 05; 15(6):. doi: 10.3390/v15061222. [PMID: 37376522]
  • Xiu Chen, Jun Li, Liqiu Kou, Xiaolu Xie, Deqing Wei, Yaling Li. Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis. Reviews in medical virology. 2023 May; ?(?):e2460. doi: 10.1002/rmv.2460. [PMID: 37198721]
  • Anchalee Avihingsanon, Ploenchan Chetchotisakd, Sasisopin Kiertiburanakul, Winai Ratanasuwan, Krittaecho Siripassorn, Khuanchai Supparatpinyo, Hal Martin, Hui Wang, TinHung Wong, Hsiu Yin Wang. Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials. HIV medicine. 2023 03; 24(3):290-300. doi: 10.1111/hiv.13386. [PMID: 36912172]
  • Charalampos D Moschopoulos, Konstantinos Protopapas, Konstantinos Thomas, Dimitra Kavatha, Antonios Papadopoulos, Anastasia Antoniadou. Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study. AIDS research and human retroviruses. 2023 02; 39(2):68-75. doi: 10.1089/aid.2022.0086. [PMID: 36401506]
  • Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove, Juan Berenguer, Michelle L D'Antoni, Christiana Blair, Susan K Chuck, David Piontkowsky, Hal Martin, Richard Haubrich, Ian R McNicholl, Joel Gallant. Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age. HIV medicine. 2023 01; 24(1):27-36. doi: 10.1111/hiv.13319. [PMID: 35527425]
  • Adem Simsek, Oguz Karabay, Ertugrul Guclu, Hande Toptan. Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV. Current HIV research. 2023; 21(5):314-322. doi: 10.2174/011570162x266922231107094649. [PMID: 37990894]
  • Nicola Squillace, Elena Ricci, Paolo Maggi, Lucia Taramasso, Barbara Menzaghi, Giuseppe Vittorio De Socio, Stefania Piconi, Benedetto Maurizio Celesia, Giancarlo Orofino, Eleonora Sarchi, Giovanni Francesco Pellicanò, Filomena Simeone, Laura Valsecchi, Alessandra Bandera, Giovanni Cenderello, Letizia Attala, Goffredo Angioni, Katia Falasca, Antonio Cascio, Olivia Bargiacchi, Antonio Di Biagio, Paolo Bonfanti. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir. PloS one. 2023; 18(8):e0289132. doi: 10.1371/journal.pone.0289132. [PMID: 37556481]
  • Eisuke Adachi, Kazuhiko Ikeuchi, Michiko Koga, Hiroshi Yotsuyanagi. Changes in Inflammatory Biomarkers When Switching from Three-Drug Regimens to Dolutegravir Plus Lamivudine in People Living with HIV. AIDS research and human retroviruses. 2022 12; 38(12):881-883. doi: 10.1089/aid.2022.0115. [PMID: 36301933]
  • Liqin Sun, Yun He, Liumei Xu, Fang Zhao, Yang Zhou, Lukun Zhang, Qiaoli Peng, Haitao Zhang, Qiuyue Zhang, Tingzhi Cao, Ying Song, Siyuan Wang, Man Rao, Xinyun Jia, Xiaoning Liu, Jing Zhou, Bin Ju, Hui Wang, Jiaye Liu. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China. Journal of acquired immune deficiency syndromes (1999). 2022 10; 91(S1):S8-S15. doi: 10.1097/qai.0000000000003040. [PMID: 36094509]
  • Botond Lakatos, Justyna Kowalska, Sergii Antoniak, Deniz Gokengin, Josip Begovac, Anna Vassilenko, Piotr Wasilewski, Lukas Fleischhans, David Jilich, Raimonda Matulionyte, Kerstin Kase, Antonios Papadopoulus, Nino Rukhadze, Arjan Harxhi, Sam Hofman, Gordana Dragovic, Marta Vasyliev, Antonija Verhaz, Nina Yancheva, Cristiana Oprea. Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19). HIV medicine. 2022 07; 23(6):693-700. doi: 10.1111/hiv.13214. [PMID: 34859557]
  • Joy Y Feng, Venice Du Pont, Darius Babusis, Calvin J Gordon, Egor P Tchesnokov, Jason K Perry, Vincent Duong, Arya Vijjapurapu, Xiaofeng Zhao, Julie Chan, Cal Cohen, Kavita Juneja, Tomas Cihlar, Matthias Götte, John P Bilello. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2. Molecules (Basel, Switzerland). 2022 Jun; 27(13):. doi: 10.3390/molecules27134212. [PMID: 35807457]
  • José L Blanco, Jhon Rojas, Elisa de Lazzari, Alexy Inciarte, Mar Subirana, Pilar Callau, María Martinez-Rebollar, Montserrat Laguno, Josep Mallolas, Lorena de la Mora, Berta Torres, Ana Gonzalez-Cordón, Esteban Martinez. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study. The Journal of antimicrobial chemotherapy. 2022 06; 77(7):1974-1979. doi: 10.1093/jac/dkac137. [PMID: 35512339]
  • Anika Shakil, Faye Y Hern, Chung Liu, Kartik Temburnikar, Pierre Chambon, Neill Liptrott, Tom O McDonald, Megan Neary, Andrew Owen, Caren Freel Meyers, Steve P Rannard. Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants. Journal of materials chemistry. B. 2022 06; 10(23):4395-4404. doi: 10.1039/d2tb00825d. [PMID: 35604111]
  • Jen-Yu Hsu, Hsin-Yun Sun, Tan-Wen Hsieh, Sui-Yuan Chang, Yu-Chung Chuang, Yu-Shan Huang, Ching-Yu Hsiao, Yi-Ching Su, Wen-Chun Liu, Shu-Fang Chang, Chien-Ching Hung. Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy. Journal of global antimicrobial resistance. 2022 Jun; 29(?):7-16. doi: 10.1016/j.jgar.2022.02.007. [PMID: 35172201]
  • Lauren Jennings, Tracy Kellermann, Matthew Spinelli, Zukiswa Nkantsu, Dolphina Cogill, Marije van Schalkwyk, Eric Decloedt, Gert van Zyl, Catherine Orrell, Monica Gandhi. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS research and human retroviruses. 2022 06; 38(6):455-462. doi: 10.1089/aid.2021.0135. [PMID: 34779228]
  • Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, Gordon Chau, Vanessa Cummings, Yaw Agyei, Paul Richardson, Philip Sullivan, Casey D Haines, Lane R Bushman, Christos Petropoulos, Deborah Persaud, Ryan Kofron, Craig W Hendrix, Peter L Anderson, Jennifer Farrior, John Mellors, Adeola Adeyeye, Alex Rinehart, Marty St Clair, Susan Ford, James F Rooney, Carrie-Anne Mathew, Portia Hunidzarira, Elizabeth Spooner, Juliet Mpendo, Gonasagrie Nair, Myron S Cohen, James P Hughes, Mina Hosseinipour, Brett Hanscom, Sinead Delany-Moretlwe, Mark A Marzinke. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. The Journal of infectious diseases. 2022 05; 225(10):1741-1749. doi: 10.1093/infdis/jiab576. [PMID: 35301540]
  • Sinead Delany-Moretlwe, James P Hughes, Peter Bock, Samuel Gurrion Ouma, Portia Hunidzarira, Dishiki Kalonji, Noel Kayange, Joseph Makhema, Patricia Mandima, Carrie Mathew, Elizabeth Spooner, Juliet Mpendo, Pamela Mukwekwerere, Nyaradzo Mgodi, Patricia Nahirya Ntege, Gonasagrie Nair, Clemensia Nakabiito, Harriet Nuwagaba-Biribonwoha, Ravindre Panchia, Nishanta Singh, Bekezela Siziba, Jennifer Farrior, Scott Rose, Peter L Anderson, Susan H Eshleman, Mark A Marzinke, Craig W Hendrix, Stephanie Beigel-Orme, Sybil Hosek, Elizabeth Tolley, Nirupama Sista, Adeola Adeyeye, James F Rooney, Alex Rinehart, William R Spreen, Kimberly Smith, Brett Hanscom, Myron S Cohen, Mina C Hosseinipour. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet (London, England). 2022 05; 399(10337):1779-1789. doi: 10.1016/s0140-6736(22)00538-4. [PMID: 35378077]
  • Jennifer Lagoutte-Renosi, Mylène Flammang, Didier Ducloux, Jamal Bamoulid, Pierre-Yves Royer, Quentin Lepiller, Anne-Laure Clairet, Siamak Davani, Patrice Muret. Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants. Journal of chemotherapy (Florence, Italy). 2022 May; 34(3):199-202. doi: 10.1080/1120009x.2021.1940436. [PMID: 34180378]
  • Lucy Campbell, Fowzia Ibrahim, Birgit Barbini, Amanda Samarawickrama, Chloe Orkin, Julie Fox, Laura Waters, Yvonne Gilleece, Shema Tariq, Frank A Post. Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir. HIV medicine. 2022 04; 23(4):362-370. doi: 10.1111/hiv.13215. [PMID: 34866304]
  • Robin Schaefer, Pedro Henrique Amparo da Costa Leite, Ronaldo Silva, Quarraisha Abdool Karim, Christopher Akolo, Carlos F Cáceres, Inês Dourado, Kimberly Green, Anita Hettema, Elske Hoornenborg, Smarajit Jana, Bernhard Kerschberger, Hally Mahler, Sindy Matse, Hamish McManus, Jean-Michel Molina, Sushena Reza-Paul, Iskandar Azwa, Maryam Shahmanesh, Doug Taylor, Hamid Vega-Ramirez, Valdiléa G Veloso, Rachel Baggaley, Shona Dalal. Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data. The lancet. HIV. 2022 04; 9(4):e242-e253. doi: 10.1016/s2352-3018(22)00004-2. [PMID: 35271825]
  • Jing Xiao, Jiang Xiao, Ying Liu, Bei Li, Leidan Zhang, Junyan Han, Hongxin Zhao. Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2022 Apr; 117(?):48-55. doi: 10.1016/j.ijid.2022.01.051. [PMID: 35108610]
  • Laura Labarthe, Thibaut Gelé, Hélène Gouget, Mariam-Sarah Benzemrane, Pauline Le Calvez, Nicolas Legrand, Olivier Lambotte, Roger Le Grand, Christine Bourgeois, Aurélie Barrail-Tran. Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice. The Journal of antimicrobial chemotherapy. 2022 03; 77(4):1094-1101. doi: 10.1093/jac/dkab501. [PMID: 35022753]
  • Derin Sevenler, Xin Niu, Sandy Dossantos, Mehmet Toner, Tim R Cressey, Rebecca D Sandlin, Paul K Drain. Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate. The Journal of antimicrobial chemotherapy. 2022 03; 77(4):996-999. doi: 10.1093/jac/dkab487. [PMID: 35038336]
  • Karla Cristina Silva Petruccelli, Djane Clarys Baía-da-Silva, Fernando Val, Monica Santos Valões, Nadia Cubas-Vega, Alexandre Vilhena Silva-Neto, Vanderson Sampaio, Aline Alencar, Roberto Pecoits-Filho, Rodrigo Carvalho Moreira, Sandra Wagner Cardoso, Ronaldo I Moreira, Iuri Costa Leite, José Valdez Madruga, Esper G Kallas, Paulo R Alencastro, Brenda Hoagland, Beatriz Grinsztejn, Valdiléa Gonçalves Veloso Santos, Marcus Vinícius Guimarães Lacerda. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil. AIDS research and therapy. 2022 02; 19(1):12. doi: 10.1186/s12981-022-00437-4. [PMID: 35209929]
  • Tippawan Siritientong, Daylia Thet, Janthima Methaneethorn, Nattawut Leelakanok. Pharmacokinetic Outcomes of the Interactions of Antiretroviral Agents with Food and Supplements: A Systematic Review and Meta-Analysis. Nutrients. 2022 Jan; 14(3):. doi: 10.3390/nu14030520. [PMID: 35276881]
  • Louise A Ouattara, Andrea R Thurman, Terry A Jacot, Mackenzie Cottrell, Craig Sykes, Kimberly Blake, Xi Fang, Susan Ju, Nikolas C Vann, Jill Schwartz, Gustavo F Doncel. Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration. Journal of acquired immune deficiency syndromes (1999). 2022 01; 89(1):87-97. doi: 10.1097/qai.0000000000002820. [PMID: 34878438]
  • Arnold Z Olali, Qiuhu Shi, Donald R Hoover, Mariana Bucovsky, Elizabeth Shane, Michael T Yin, Ryan D Ross. Bone and fat hormonal crosstalk with antiretroviral initiation. Bone. 2022 01; 154(?):116208. doi: 10.1016/j.bone.2021.116208. [PMID: 34547525]
  • Borja Mora-Peris, Michael R Keegan, Sujan Dilly Penchala, Jaime H Vera, Jonathan Underwood, Maryam Khan, Carolina Herrera, Dietmar Fuchs, Adriano Boasso, Saye Khoo, Alan Winston. Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial. HIV research & clinical practice. 2021 12; 22(6):151-159. doi: NULL. [PMID: 34743666]
  • Maartje Dijkstra, Henrieke Prins, Jan M Prins, Peter Reiss, Charles Boucher, Annelies Verbon, Casper Rokx, Godelieve de Bree. Cohort profile: the Netherlands Cohort Study on Acute HIV infection (NOVA), a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment. BMJ open. 2021 11; 11(11):e048582. doi: 10.1136/bmjopen-2020-048582. [PMID: 34845066]
  • Douglas Drak, Hamish Mcmanus, Tobias Vickers, Jack E Heron, Stefanie Vaccher, Iryna Zablotska, Rebecca Guy, Benjamin Bavinton, Fengyi Jin, Andrew E Grulich, Mark Bloch, Catherine C O'Connor, David M Gracey. Renal impairment in a large-scale HIV preexposure prophylaxis implementation cohort. AIDS (London, England). 2021 11; 35(14):2319-2326. doi: 10.1097/qad.0000000000003035. [PMID: 34310371]
  • Thibaut Gelé, Antoine Chéret, Alicia Castro Gordon, Lionelle Nkam, Valérie Furlan, Coralie Pallier, Pierre-Hadrien Becker, Pilartxo Catalan, Cécile Goujard, Anne-Marie Taburet, Jacques Gasnault, Hélène Gouget, Aurélie Barrail-Tran. Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment. The Journal of antimicrobial chemotherapy. 2021 11; 76(12):3280-3285. doi: 10.1093/jac/dkab334. [PMID: 34508640]
  • Bo-Huang Liou, Chih-Ning Cheng, Ya-Ting Lin, Yu-Jou Lin, Yu-Chung Chuang, Kuan-Yin Lin, Wen-Chun Liu, Shu-Wen Lin, Ching-Hua Kuo, Hsin-Yun Sun, Chien-Ching Hung. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. Journal of the International AIDS Society. 2021 11; 24(11):e25844. doi: 10.1002/jia2.25844. [PMID: 34822220]
  • Juan Berenguer, Cristina Díez, María Martín-Vicente, Rafael Micán, María J Pérez-Elías, Lucio J García-Fraile, Francisco Vidal, Inés Suárez-García, Daniel Podzamczer, Jorge Del Romero, Federico Pulido, José A Iribarren, Félix Gutiérrez, Eva Poveda, Carlos Galera, Rebeca Izquierdo, Víctor Asensi, Joaquín Portilla, Juan C López, José R Arribas, Santiago Moreno, Juan González-García, Salvador Resino, Inmaculada Jarrín. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021 Nov; 27(11):1678-1684. doi: 10.1016/j.cmi.2021.06.023. [PMID: 34186209]
  • Huan Xia, Xiao-Jie Huang, Yue Hu, Li-Ying Gao, Yue Wu, Hao Wu, Zhong-Fang Yan, Ping Ma. Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV. Chinese medical journal. 2021 Oct; 134(23):2850-2856. doi: 10.1097/cm9.0000000000001824. [PMID: 34653085]
  • Erin M B Scholz, Yanguang Cao, Angela D M Kashuba. A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models. The Journal of antimicrobial chemotherapy. 2021 10; 76(11):2890-2893. doi: 10.1093/jac/dkab298. [PMID: 34374767]
  • Robert M Grant, Marion Pellegrini, Patricia A Defechereux, Peter L Anderson, Michelle Yu, David V Glidden, Joshua O'Neal, Jenna Yager, Shalender Bhasin, Jae Sevelius, Madeline B Deutsch. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 10; 73(7):e2117-e2123. doi: 10.1093/cid/ciaa1160. [PMID: 32766890]
  • Arkaitz Imaz, Juan M Tiraboschi, Jordi Niubó, Javier Martinez-Picado, Mackenzie L Cottrell, Pere Domingo, Ivan Chivite, Eugenia Negredo, Amanda Schauer, Brian Van Horne, Sandra Morenilla, Víctor Urrea, Ana Silva-Klug, Sofía Scévola, Benito Garcia, Angela D M Kashuba, Daniel Podzamczer. Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 10; 73(7):e1991-e1999. doi: 10.1093/cid/ciaa1416. [PMID: 32945851]
  • Sorour Khayyatnejad Shoushtari, Khalid Zoghebi, Muhammad Imran Sajid, Rakesh Kumar Tiwari, Keykavous Parang. Hybrid Cyclic-Linear Cell-Penetrating Peptides Containing Alternative Positively Charged and Hydrophobic Residues as Molecular Transporters. Molecular pharmaceutics. 2021 10; 18(10):3909-3919. doi: 10.1021/acs.molpharmaceut.1c00594. [PMID: 34491768]
  • Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, Graeme Moyle. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients. HIV research & clinical practice. 2021 10; 22(5):128-139. doi: . [PMID: 34551678]
  • Richard E Haaland, Amy Martin, Melkam Mengesha, Chuong Dinh, Jeffrey Fountain, L Davis Lupo, LaShonda Hall, Christopher Conway-Washington, Colleen F Kelley. Short Communication: Evaluation of Antiretroviral Drug Concentrations in Minimally Invasive Specimens for Potential Development of Point-of-Care Drug Assays. AIDS research and human retroviruses. 2021 10; 37(10):744-747. doi: 10.1089/aid.2020.0187. [PMID: 33461414]
  • Wei-Chieh Huang, Chun-Kai Huang, Sung-Hsi Huang, Shu-Wen Lin, Shyh-Tyan Ou, Yi-Ting Chen, Ya-Wen Chen, Shu-Yuan Chang, Wen-Chun Liu, Hsin-Yun Sun, Chien-Ching Hung. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2021 Oct; 54(5):944-951. doi: 10.1016/j.jmii.2020.06.010. [PMID: 32675042]
  • Jingchuan Shang, Rui Tan, Junqing Yang, Bo Yan, Xiaoni Zhong, Yan Zhang, Bayan Alnajebi, Qing Ma, Ailong Huang. Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China. Journal of infection and public health. 2021 Sep; 14(9):1169-1173. doi: 10.1016/j.jiph.2021.07.018. [PMID: 34391173]
  • Ashley Otto, Patricia Pecora Fulco. A retrospective evaluation of highly active antiretroviral therapy simplification in patients with end-stage renal disease receiving hemodialysis. International journal of STD & AIDS. 2021 09; 32(10):963-967. doi: 10.1177/09564624211011902. [PMID: 33969749]
  • Thornthun Ueaphongsukkit, Sivaporn Gatechompol, Anchalee Avihingsanon, Jerasit Surintrspanont, Kroonpong Iampenkhae, Yingyos Avihingsanon, Suwasin Udomkarnjananun. Tenofovir alafenamide nephrotoxicity: a case report and literature review. AIDS research and therapy. 2021 08; 18(1):53. doi: 10.1186/s12981-021-00380-w. [PMID: 34419091]
  • Richard E Haaland, Jeffrey Fountain, Chuong Dinh, L Davis Lupo, Amy Martin, Christopher Conway-Washington, LaShonda Hall, Colleen F Kelley, J Gerardo Garcia-Lerma, Walid Heneine. Antiretroviral drug exposure in urethral and glans surface sampling of the penis. The Journal of antimicrobial chemotherapy. 2021 08; 76(9):2368-2374. doi: 10.1093/jac/dkab155. [PMID: 34007982]
  • Emre Aydin, Fatma Yilmaz Aydin, Yakup Demir, Yasar Yildirim, Mustafa Kemal Celen. Evaluation of kidney function tests in HIV-positive patients receiving combined antiretroviral therapy. International journal of clinical practice. 2021 Aug; 75(8):e14542. doi: 10.1111/ijcp.14542. [PMID: 34137140]
  • M Gutiérrez-Lorenzo, D Rubio-Calvo, J Urda-Romacho. [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2021 Aug; 34(4):315-319. doi: 10.37201/req/148.2020. [PMID: 34032111]
  • Rogers Sekabira, Ian McGowan, Krista Yuhas, Rhonda M Brand, Mark A Marzinke, Yukari C Manabe, Ian Frank, Joseph Eron, Raphael J Landovitz, Peter Anton, Ross D Cranston, Peter Anderson, Kenneth H Mayer, K Rivet Amico, Timothy J Wilkin, Wairimu Chege, Adeodata R Kekitiinwa, Marybeth McCauley, Roy M Gulick, Craig W Hendrix. Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. AIDS (London, England). 2021 08; 35(10):1585-1595. doi: 10.1097/qad.0000000000002907. [PMID: 33831911]
  • Colette DeJong, Matthew A Spinelli, Hideaki Okochi, Monica Gandhi. Tenofovir-based PrEP for COVID-19: an untapped opportunity?. AIDS (London, England). 2021 07; 35(9):1509-1511. doi: 10.1097/qad.0000000000002877. [PMID: 33710026]
  • Paul E Sax, Jürgen K Rockstroh, Anne F Luetkemeyer, Yazdan Yazdanpanah, Douglas Ward, Benoit Trottier, Armin Rieger, Hui Liu, Rima Acosta, Sean E Collins, Diana M Brainard, Hal Martin. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 07; 73(2):e485-e493. doi: 10.1093/cid/ciaa988. [PMID: 32668455]
  • Zhen Wang, Bin Zhao, Minghui An, Wei Song, Xue Dong, Xin Li, Lu Wang, Lin Wang, Wen Tian, Haibo Ding, Xiaoxu Han. Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018. BMC infectious diseases. 2021 Jul; 21(1):668. doi: 10.1186/s12879-021-06312-3. [PMID: 34243716]
  • Brian R Wood, Anton L Pozniak. Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance!. AIDS (London, England). 2021 07; 35(8):1305-1307. doi: 10.1097/qad.0000000000002903. [PMID: 34076616]
  • Thibault Mesplède. Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults. Expert opinion on pharmacotherapy. 2021 Jul; 22(10):1245-1251. doi: 10.1080/14656566.2021.1902504. [PMID: 33691554]
  • Hideaki Okochi, Alexander Louie, Nhi Phung, Kevin Zhang, Regina M Tallerico, Karen Kuncze, Matthew A Spinelli, Catherine A Koss, Leslie Z Benet, Monica Gandhi. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART. Drug testing and analysis. 2021 Jul; 13(7):1354-1370. doi: 10.1002/dta.3033. [PMID: 33742745]
  • Santiago Jiménez de Ory, Carolina Beltrán-Pavez, Miguel Gutiérrez-López, María Del Mar Santos, Luis Prieto, Talía Sainz, Sara Guillen, David Aguilera-Alonso, Cristina Díez, Jose Ignacio Bernardino, María José Mellado, José Tomás Ramos, África Holguín, Marisa Navarro. Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure. The Journal of antimicrobial chemotherapy. 2021 06; 76(7):1886-1892. doi: 10.1093/jac/dkab080. [PMID: 33734374]
  • Oliver Ackaert, David McDougall, Carlos Pérez-Ruixo, Juan Jose Pérez-Ruixo, John Jezorwski, Herta M Crauwels. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies). The AAPS journal. 2021 06; 23(4):82. doi: 10.1208/s12248-021-00607-8. [PMID: 34100149]
  • Emma Touizer, Aljawharah Alrubayyi, Chloe Rees-Spear, Natasha Fisher-Pearson, Sarah A Griffith, Luke Muir, Pierre Pellegrino, Laura Waters, Fiona Burns, Sabine Kinloch, Sarah Rowland-Jones, Ravindra K Gupta, Richard Gilson, Dimitra Peppa, Laura E McCoy. Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV. The lancet. HIV. 2021 06; 8(6):e317-e318. doi: 10.1016/s2352-3018(21)00099-0. [PMID: 34087093]
  • Kelly A Johnson, Miao-Jung Chen, Robert Kohn, Darpun Sachdev, Oliver Bacon, Sulggi Lee, Stephanie E Cohen. Acute HIV at the Time of Initiation of Pre-exposure or Post-exposure Prophylaxis: Impact on Drug Resistance and Clinical Outcomes. Journal of acquired immune deficiency syndromes (1999). 2021 06; 87(2):818-825. doi: 10.1097/qai.0000000000002638. [PMID: 33512849]
  • Thomas L Nickolas, Jonathan Barasch, Kenneth K Mugwanya, Andrea D Branch, Renee Heffron, Valentine Wanga, Nelly R Mugo, Allan Ronald, Connie Celum, Deborah Donnell, Jared M Baeten, Christina M Wyatt. Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis. AIDS (London, England). 2021 06; 35(7):1147-1149. doi: 10.1097/qad.0000000000002865. [PMID: 33710023]
  • Smarajit Jana, Protim Ray, Soma Roy, Abhijit Kadam, Raman R Gangakhedkar, B B Rewari, Stephen Moses, Marissa L Becker. Successful integration of HIV pre-exposure prophylaxis into a community-based HIV prevention program for female sex workers in Kolkata, India. International journal of STD & AIDS. 2021 06; 32(7):638-647. doi: 10.1177/0956462420983992. [PMID: 33596735]
  • Gianmaria Baldin, Arturo Ciccullo, Francesca Lombardi, Anna D'Angelillo, Alex Dusina, Arianna Emiliozzi, Damiano Farinacci, Davide Moschese, Chiara Picarelli, Alberto Borghetti, Simona Di Giambenedetto. Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice. AIDS research and human retroviruses. 2021 06; 37(6):429-432. doi: 10.1089/aid.2020.0219. [PMID: 33280486]
  • Xiaomei I Liu, John N van den Anker, Gilbert J Burckart, André Dallmann. Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups. Journal of clinical pharmacology. 2021 06; 61 Suppl 1(?):S94-S107. doi: 10.1002/jcph.1845. [PMID: 34185902]
  • Xiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, Dionna J Green, Gilbert J Burckart, Tim R Cressey, Mark Mirochnick, Brookie M Best, John N van den Anker, André Dallmann. Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. Clinical pharmacokinetics. 2021 06; 60(6):795-809. doi: 10.1007/s40262-020-00977-w. [PMID: 33527213]
  • Teodora Pene Dumitrescu, Samit R Joshi, Jianfeng Xu, Joyce Zhan, Mark Johnson, Laurie Butcher, Eric Zimmerman, Lindsey Webster, Antonia M Davidson, Max Lataillade, Sherene Min. A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants. Antimicrobial agents and chemotherapy. 2021 05; 65(6):. doi: 10.1128/aac.02173-20. [PMID: 33753329]
  • Thierry Prazuck, Renaud Verdon, Gwenaël Le Moal, Faïza Ajana, Louis Bernard, Simon Sunder, Mariam Roncato-Saberan, Diane Ponscarme, Manuel Etienne, Jean-Paul Viard, Thierry Pasdeloup, Iuliana Darasteanu, Gilles Pialoux, Arnaud de la Blanchardière, Véronique Avettand-Fènoël, Jean-Jacques Parienti, Laurent Hocqueloux. Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial. The Journal of antimicrobial chemotherapy. 2021 05; 76(6):1564-1572. doi: 10.1093/jac/dkab038. [PMID: 33724373]
  • Fehmi Tabak, Esra Zerdali, Ozlem Altuntaş, Alper Gunduz, Sibel Bolukcu, Bilgul Mete, Inci Y Nakir, Hayat Kumbasar Karaosmanoglu, Dilek S Yildiz, Meliha Meric Koc, İlyas Dokmetas. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data. International journal of STD & AIDS. 2021 05; 32(6):562-569. doi: 10.1177/0956462420983692. [PMID: 33599173]
  • Mark Nelson, Alan Winston, Andrew Hill, Rosie Mngqibisa, Ayesha Bassa, Chloe Orkin, Mohammed Rassool, Anthony Rodgers, Valerie Teal, Sushma Kumar, Hedy Teppler. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS (London, England). 2021 04; 35(5):759-767. doi: 10.1097/qad.0000000000002804. [PMID: 33587439]
  • Angela Shogbon Nwaesei, Pamela M Moye-Dickerson, Robin Henry Dretler. Efavirenz-Induced Vanishing Bile Duct Syndrome: A Case Report. Journal of pharmacy practice. 2021 Apr; 34(2):319-324. doi: 10.1177/0897190019868358. [PMID: 31451051]
  • Yu-Shan Huang, Chien-Yu Cheng, Bo-Huang Liou, Po-Liang Lu, Shu-Hsing Cheng, Yuan-Ti Lee, Chun-Eng Liu, Hsin-Yun Sun, Chia-Jui Yang, Hung-Jen Tang, Shih-Ping Lin, Mao-Wang Ho, Sung-Hsi Huang, Hung-Chin Tsai, Chen-Hsiang Lee, Chien-Ching Hung. Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. Journal of acquired immune deficiency syndromes (1999). 2021 04; 86(4):473-481. doi: 10.1097/qai.0000000000002589. [PMID: 33273214]
  • Subhra Mandal, Pavan Kumar Prathipati, Shawnalyn W Sunagawa, Christopher J Destache. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis. Antimicrobial agents and chemotherapy. 2021 03; 65(4):. doi: 10.1128/aac.02320-20. [PMID: 33526487]
  • R N Dallocchio, A Dessì, A De Vito, G Delogu, P A Serra, G Madeddu. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?. European review for medical and pharmacological sciences. 2021 Mar; 25(5):2435-2448. doi: 10.26355/eurrev_202103_25285. [PMID: 33755983]
  • Elena Bekerman, Stephanie Cox, Darius Babusis, Federico Campigotto, Moupali Das, Dan H Barouch, Tomas Cihlar, Christian Callebaut. Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection. The Journal of antimicrobial chemotherapy. 2021 02; 76(3):692-698. doi: 10.1093/jac/dkaa476. [PMID: 33202006]
  • Nomathemba C Chandiwana, Matthew Chersich, W D François Venter, Godspower Akpomiemie, Andrew Hill, Bryony Simmons, Shahin Lockman, Celicia M Serenata, Lee Fairlie, Michelle A Moorhouse. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. AIDS (London, England). 2021 02; 35(2):205-211. doi: 10.1097/qad.0000000000002741. [PMID: 33086234]
  • F Ibrahim, A Samarawickrama, L Hamzah, R Vincent, Y Gilleece, L Waters, S Kegg, B Barbini, L Campbell, F A Post. Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG. HIV medicine. 2021 02; 22(2):83-91. doi: 10.1111/hiv.12961. [PMID: 32985122]
  • Randy M Stalter, Jared M Baeten, Deborah Donnell, Matthew A Spinelli, David V Glidden, Warren C Rodrigues, Guohong Wang, Michael Vincent, Nelly Mugo, Andrew Mujugira, Mark Marzinke, Craig Hendrix, Monica Gandhi. Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 02; 72(3):486-489. doi: 10.1093/cid/ciaa785. [PMID: 33527128]
  • Siobhan Quirke, Laura Quinn, Deborah Hegarty, Aisling Loy, Fiona Lyons, Fiona Mulcahy, Emma Devitt. Virtual HIV pre-exposure prophylaxis outpatient service in the era of COVID-19. International journal of STD & AIDS. 2021 01; 32(1):100-103. doi: 10.1177/0956462420961951. [PMID: 33050787]
  • Emily R Bowman, Cheryl Cameron, Brian Richardson, Manjusha Kulkarni, Janelle Gabriel, Aaren Kettelhut, Lane Hornsby, Jesse J Kwiek, Abigail Norris Turner, Carlos Malvestutto, Jose Bazan, Susan L Koletar, Susanne Doblecki-Lewis, Michael M Lederman, Mark Cameron, Nichole R Klatt, Jordan E Lake, Nicholas T Funderburg. In Vitro Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles. Antimicrobial agents and chemotherapy. 2020 12; 65(1):. doi: 10.1128/aac.01755-20. [PMID: 33020165]
  • Nadège Néant, Minh Patrick Lê, Naïm Bouazza, Florence Gattacceca, Yazdan Yazdanpanah, Catherine Dhiver, Sylvie Bregigeon, Saadia Mokhtari, Gilles Peytavin, Catherine Tamalet, Diane Descamps, Bruno Lacarelle, Caroline Solas. Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients. British journal of clinical pharmacology. 2020 12; 86(12):2404-2413. doi: 10.1111/bcp.14344. [PMID: 32374049]
  • Rima K Acosta, Madeleine Willkom, Kristen Andreatta, Hui Liu, Ross Martin, Aiyappa Parvangada, Hal Martin, Sean Collins, Kirsten L White. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. Journal of acquired immune deficiency syndromes (1999). 2020 11; 85(3):363-371. doi: 10.1097/qai.0000000000002454. [PMID: 32701823]
  • Julia Del Amo, Rosa Polo, Santiago Moreno, Asunción Díaz, Esteban Martínez, José Ramón Arribas, Inma Jarrín, Miguel A Hernán. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study. Annals of internal medicine. 2020 10; 173(7):536-541. doi: 10.7326/m20-3689. [PMID: 32589451]
  • David M Stevens, Pavan Adiseshaiah, Siva S K Dasa, Tim M Potter, Sarah L Skoczen, Kelsie S Snapp, Edward Cedrone, Nimit Patel, Kathleen Busman-Sahay, Elias P Rosen, Craig Sykes, Mackenzie Cottrell, Marina A Dobrovolskaia, Jacob D Estes, Angela D M Kashuba, Stephan T Stern. Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV. Molecular pharmaceutics. 2020 10; 17(10):3794-3812. doi: 10.1021/acs.molpharmaceut.0c00562. [PMID: 32841040]
  • Jessica Tarleton, Beatrice A Chen, Leslie A Meyn, Craig W Hendrix, Mark A Marzinke, Sharon L Achilles. Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women. Journal of acquired immune deficiency syndromes (1999). 2020 10; 85(2):182-188. doi: 10.1097/qai.0000000000002421. [PMID: 32568766]
  • Willem D F Venter, Simiso Sokhela, Bryony Simmons, Michelle Moorhouse, Lee Fairlie, Nkuli Mashabane, Celicia Serenata, Godspower Akpomiemie, Masebole Masenya, Ambar Qavi, Nomathemba Chandiwana, Kaitlyn McCann, Shane Norris, Matthew Chersich, Gary Maartens, Samanta Lalla-Edward, Alinda Vos, Polly Clayden, Elaine Abrams, Natasha Arulappan, Andrew Hill. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet. HIV. 2020 10; 7(10):e666-e676. doi: 10.1016/s2352-3018(20)30241-1. [PMID: 33010240]
  • Guan-Jhou Chen, Yu-Lin Lee, Chen-Hsiang Lee, Hsin-Yun Sun, Chien-Yu Cheng, Hung-Chin Tsai, Sung-Hsi Huang, Yi-Chieh Lee, Min-Han Hsieh, Sui-Yuan Chang, Yu-Chung Chuang, Li-Shin Su, Sui-Fang Chang, Hung-Jen Tang, Chien-Ching Hung. Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV. The Journal of antimicrobial chemotherapy. 2020 10; 75(10):2986-2993. doi: 10.1093/jac/dkaa287. [PMID: 32737511]
  • Julie B Dumond, Camden P Bay, Julie A E Nelson, Angel Davalos, Andrew Edmonds, Kristina De Paris, Craig Sykes, Kathryn Anastos, Roopali Sharma, Seble Kassaye, Bani Tamraz, Audrey L French, Stephen Gange, Ighovwerha Ofotokun, Margaret A Fischl, David E Vance, Adaora A Adimora. Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine. Antimicrobial agents and chemotherapy. 2020 08; 64(9):. doi: 10.1128/aac.00177-20. [PMID: 32631821]
  • Qing Ma, Andrew J Ocque, Gene D Morse, Chelsea Sanders, Alina Burgi, Susan J Little, Scott L Letendre. Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 08; 71(4):982-988. doi: 10.1093/cid/ciz926. [PMID: 31560741]
  • Matthew A Spinelli, Jessica E Haberer, Peter R Chai, Jose Castillo-Mancilla, Peter L Anderson, Monica Gandhi. Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. Current HIV/AIDS reports. 2020 08; 17(4):301-314. doi: 10.1007/s11904-020-00502-5. [PMID: 32424549]
  • Tim R Cressey, Oraphan Siriprakaisil, Rachel W Kubiak, Virat Klinbuayaem, Pra-Ornsuda Sukrakanchana, Justice Quame-Amaglo, Hideaki Okochi, Yardpiroon Tawon, Ratchada Cressey, Jared M Baeten, Monica Gandhi, Paul K Drain. Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020 Aug; 97(?):365-370. doi: 10.1016/j.ijid.2020.06.037. [PMID: 32553717]
  • Collins C Iwuji, Duncan Churchill, Stephen Bremner, Nicky Perry, Ye To, Debbie Lambert, Chloe Bruce, Laura Waters, Chloe Orkin, Anna Maria Geretti. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial. BMC infectious diseases. 2020 Jul; 20(1):524. doi: 10.1186/s12879-020-05240-y. [PMID: 32689975]
  • Eisuke Adachi, Makoto Saito, Kazuhiko Ikeuchi, Tokio Hoshina, Hiroshi Yotsuyanagi. Cases of coronavirus disease-2019 in HIV-infected transgender women. AIDS (London, England). 2020 07; 34(9):1435-1436. doi: 10.1097/qad.0000000000002573. [PMID: 32590441]
  • Harry Coleman, Luke B Snell, Rebecca Simons, Sam T Douthwaite, Ming J Lee. Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV. AIDS (London, England). 2020 07; 34(8):1258-1260. doi: 10.1097/qad.0000000000002571. [PMID: 32501852]